Comment on ‘Cutaneous manifestations in COVID‐19: a first perspective’ by Recalcati S

Archive ouverte

Hedou, M. | Carsuzaa, F. | Chary, E. | Hainaut, E. | Cazenave‐roblot, F. | Masson Regnault, M.

Edité par CCSD ; Wiley -

International audience. Since the coronavirus disease 2019 (COVID 19) outbreak was first reported in the Chinese city of Wuhan on December 31, 2019, it has stricken more than 1,000,000 persons worldwide, of whom over 50,000 have died (1). Having been infected by severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2), patients with COVID‐19 mainly present with fever and respiratory symptoms (2). Isolated sudden onset anosmia has also frequently been reported (3). Less frequently, rhinorrhea, diarrhoea and dysgeusia may be associated. While only a few reports have evoked cutaneous manifestations (4), we read with interest an initial study on the topic entitled “Cutaneous manifestations in COVID‐19: a first perspective ” by Recalcati S. (5).

Consulter en ligne

Suggestions

Du même auteur

Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ

Archive ouverte | Masson Regnault, M. | CCSD

International audience

Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6–11 years): data from a French multicentre retrospective cohort in daily practice

Archive ouverte | Lasek, Audrey | CCSD

International audience. Background: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD).Objective: The aim of this study was to evaluate the effective...

Les mélanomes d’apparition précoce (congénitaux, néonataux, du nourrisson) : revue systématique des cas de la littérature

Archive ouverte | Masson Regnault, M. | CCSD

International audience

Chargement des enrichissements...